FDA Approves IV Enzyme Tx for Rare ASMD – Xenpozyme
The FDA recently approved a new infused therapy, Xenpozyme (olipudase-alfa) from Genzyme , for pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare
The FDA recently approved a new infused therapy, Xenpozyme (olipudase-alfa) from Genzyme , for pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare
The FDA recently approved a novel infused therapy, Spevigo (spesolimab-sbzo) from Boehringer Ingelheim), with an indication for the treatment of generalized pustular psoriasis (GPP) flares
The FDA recently approved the fourth biosimilar to Genentech’s Avastin, Vegzelma (bevacizumab-adcd) from Celltrion USA. Vegzelma is an infused therapy administered by a healthcare professional.
The FDA recently approved a novel infused therapy, Terlivaz (terlipressin) from Mallinckrodt, with an indication for hepatorenal syndrome (HRS) with rapid reduction in kidney function. There are
The FDA recently approved a BLA for Rolvedon (eflapegrastim-xnst) from Spectrum Pharmaceuticals. It has an indication to decrease the incidence of infection, as manifested by febrile
The FDA has just approved an oral suspension therapy, Relyvrio from Amylyx Pharmaceuticals, for ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease). Relyvrio joins a surprisingly
A few weeks ago, a press release from Shields Health announced that it had obtained accreditation from URAC…… not as a dispensing specialty pharmacy but,
We reviewed a report from the Office of Disease Prevention and Health Promotion, a part of the U.S. Department of Health and Human Services some
It’s been a rocky road for CVS of late. In July, CVS was assessed a multi-million $ fine in an arbitration case filed by a small
We’ve written numerous times about value-based contracting (VBC)….. including earlier this week. When it emerged a few years ago there was much hope that VBC